Alexion Pharmaceuticals, Inc. (ALXN) |
|
182.5 0 (0%)
|
10-01 10:15 |
|
Open: |
181.04 |
Pre. Close: |
182.5 |
|
High:
|
182.67 |
Low:
|
180.21 |
|
Volume:
|
3 |
Market Cap:
|
40,336(M) |
|
|
|
|
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
211.18 - 212.67 |
212.67 - 213.83 |
|
Low:
|
205.68 - 207.27 |
207.27 - 208.51 |
|
Close:
|
206.91 - 209.34 |
209.34 - 211.23 |
|
Technical analysis |
as of: 2022-09-30 4:26:06 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 272.18 One year: 292.43 |
| Support: |
Support1: 205 Support2: 170.55 |
| Resistance: |
Resistance1: 233.03 Resistance2: 250.36 |
| Pivot: |
221.39  |
| Moving Average: |
MA(5): 209.48 MA(20): 223.23
MA(100): 234.39 MA(250): 250.31 |
| MACD: |
MACD(12,26): -8.2 Signal(9): -6.7 |
| Stochastic oscillator: |
%K(14,3): 13.3  %D(3): 10.6 |
| RSI: |
RSI(14): 30.4 |
| 52-week: |
High: 299.98 Low: 205 |
| Average Vol(K): |
3-Month: 9 (K) 10-Days: 10 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALX ] has closed above bottom band by 18.1%. Bollinger Bands are 50.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 29 Sep 2022
US close: Stocks weaker on hawkish Fed commentary | Financial News - London South East
Wed, 28 Sep 2022
Apellis Pharmaceuticals Stock: Trying To Develop A Blockbuster Franchise (NASDAQ:APLS) - Seeking Alpha
Thu, 23 Jun 2022
ALXN1840 shows rapid and sustained improvement in copper mobilisation from tissues, potentially closing treatment gaps for Wilson disease community - AstraZeneca
Wed, 21 Jul 2021
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases - FiercePharma
Wed, 21 Jul 2021
Acquisition of Alexion completed - AstraZeneca
Thu, 15 Jul 2021
Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
58.7 (%) |
|
% Held by Institutions
|
39.9 (%) |
|
Shares Short
|
138 (K) |
|
Shares Short P.Month
|
139 (K) |
Stock Financials |
|
EPS
|
22.65 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
23.22 |
|
EPS Est Next Year
|
23.62 |
|
Book Value (p.s.)
|
48.93 |
|
Profit Margin (%)
|
59.9 |
|
Operating Margin (%)
|
37.3 |
|
Return on Assets (ttm)
|
3.2 |
|
Return on Equity (ttm)
|
50.9 |
|
Qtrly Rev. Growth
|
-3 |
|
Gross Profit (p.s.)
|
22.51 |
|
Sales Per Share
|
38.67 |
|
EBITDA (p.s.)
|
20.53 |
|
Qtrly Earnings Growth
|
-42.8 |
|
Operating Cash Flow
|
149 (M) |
|
Levered Free Cash Flow
|
86 (M) |
Stock Valuations |
|
PE Ratio
|
9.22 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.27 |
|
Price to Sales
|
5.4 |
|
Price to Cash Flow
|
7.15 |
Stock Dividends |
|
Dividend
|
4.5 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
2.1% |
|
Dividend Pay Date
|
2021-11-18 |
|
Ex-Dividend Date
|
2021-11-04 |
|
7 Binary Options
|
|
Your Ad Here
|
|
